tetanus diphtheria toxoid-National Institute of Allergy and Infectious Diseases (NIAID)-pneumococcal infection-rabies-tetanus

This entry refers to a specific regimen of FDA-approved vaccines—including tetanus-diphtheria toxoid, pneumococcal vaccines (such as Pneumovax and Prevnar), and rabies vaccine (such as Rabavert)—used by the National Institute of Allergy and Infectious Diseases (NIAID) to evaluate the functional immune response in patients with known or suspected primary immune disorders. The protocol measures the ability of a patient's T and B cells to generate specific antibodies following vaccination, which serves as a diagnostic tool for assessing the severity of immune deficiency or the success of immune reconstitution therapies like bone marrow transplantation or gene therapy. The vaccines are administered as part of a clinical trial protocol (NCT00001355) to determine in vivo immune function.

Brand names

PneumovaxPrevnarRabavert

Other names

Tetanus-diphtheria booster